fda compounding semaglutide enforcement 2025 news is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified GLP-1 Compounding: When Innovation May

This is the first phase 3 readout of that triple mechanism specifically in a type 2 diabetes population rather than obesity alone, and the glycemic effect size is notable relative to existing incretin based therapies

These side effects are usually mild and dont last long

Using both pharmacological and genetic approaches, we demonstrated that liraglutide retained antidepressant efficacy in GLP-1R antagonist-Exn9-treated mice or in Glp1r / mice, whereas gut microbiota depletion abolished its effects

Venting Gastrostomy or Jejunostomy In patients with significant upper GI motility disorders, surgically placed venting gastrostomy, with or without a venting enterostomy, has been found to reduce hospitalizations

Most patients find they feel intoxicated faster and experience worse hangovers